Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). SMO Clinplus Co's share price for the quarter that ended in Jun. 2026 was ¥45.38. SMO Clinplus Co's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 79.0 Mil. Therefore, SMO Clinplus Co's market cap for the quarter that ended in Jun. 2026 was ¥3,585.2 Mil.
SMO Clinplus Co's quarterly market cap
increased
from Dec. 2025 (¥4,111.4 Mil) to Mar. 2026 (¥4,381.6 Mil) but then
declined
from Mar. 2026 (¥4,381.6 Mil) to Jun. 2026 (¥3,585.2 Mil).
SMO Clinplus Co's annual market cap
declined
from Dec. 2023 (¥3,883.7 Mil) to Dec. 2024 (¥2,143.5 Mil) but then
increased
from Dec. 2024 (¥2,143.5 Mil) to Dec. 2025 (¥4,111.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SMO Clinplus Co's Enterprise Value for Today is ¥2,365.4 Mil.
SMO Clinplus Co (SZSE:301257) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
SMO Clinplus Co Market Cap Related Terms
SMO Clinplus Co Market Cap Historical Data
* Premium members only.
The historical data trend for SMO Clinplus Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:301257 vs TMO, DHR, NTRA: Market Cap Comparison
For the Diagnostics & Research subindustry, SMO Clinplus Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMO Clinplus Co Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's Market Cap distribution charts can be found below:
* The bar in red indicates where SMO Clinplus Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SMO Clinplus Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMO Clinplus Co (SZSE:301257) has a Market Cap of ¥2,939.0 Mil as of Sep. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SMO Clinplus Co and its competitors. According to the industry distribution chart, SMO Clinplus Co ranks #70 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 32.3%.
Is SMO Clinplus Co's Market Cap too high?
SMO Clinplus Co's current Market Cap is ¥2,939.0 Mil. Based on the distribution chart, SMO Clinplus Co ranks #70 out of 217 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, SMO Clinplus Co has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SMO Clinplus Co's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SMO Clinplus Co ranks #70 out of 217 companies for Market Cap. This puts SMO Clinplus Co in the upper half of its industry. The industry median Market Cap is 62.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 62.51, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SMO Clinplus Co and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 62.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SMO Clinplus Co's current Market Cap is ¥2,939.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMO Clinplus Co stock overvalued right now?
Based on GuruFocus' analysis, SMO Clinplus Co (SZSE:301257) is currently considered Fairly Valued. The stock's GF Value™ is ¥38.90, compared to a current price of ¥37.20 — trading 4.4% below its estimated fair value. The current Market Cap is ¥2,939.0 Mil. SMO Clinplus Co's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For SMO Clinplus Co (SZSE:301257), the current Market Cap is ¥2,939.0 Mil as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMO Clinplus Co (SZSE:301257) Overvalued in 2026?
Based on GuruFocus' analysis, SMO Clinplus Co stock appears to be undervalued.
The current stock price of ¥37.20 is trading 4.4% below its estimated GF Value™ of ¥38.90.
GuruFocus considers SMO Clinplus Co to be Fairly Valued.
Key valuation signals for SZSE:301257:
Market Cap: ¥2,939.0 Mil
GF Value™: ¥38.90 vs. price of ¥37.20 (4.4% below fair value)
No single metric tells the full story. See the SZSE:301257 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies, and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
91GF Score
Get the complete analysis for SZSE:301257
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301257 has been successfully added to your 
